Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

ÂConference call 26 September at 14.00 CET8 AM ETÂ 32 2 400 6926 code 8889838 Mechelen Belgium; 26 September 2016 02.00 CET Galapagos NV Euronext & NASDAQ GLPG reports that Dr Severine Vermeire principal investigator of the FITZROY Phase 2 study...